

Strategic Research & Innovation Committee

minutes

Minutes of the Strategic Research & Innovation meeting held on 27th February 2024

Present:	Bob Burgoyne	Non-Executive Director (Chair)
	Liz Bishop	Chief Executive Officer
	Prof Jay Wright	Clinical Lead for Research and Director of Research & Innovation
	Keith Wilson	Patient Research Ambassador
	Jennifer Crooks	Deputy Director of Research & Innovation
	Jonathan Mathews	Chief Operating Officer
	Prof Reecha Sofat	Head of Department Pharmacology and Therapeutics, University of Liverpool
In Attendance:	Ian Jones	
	Jennifer Ohlsson	Senior Executive Assistant (Minutes)
Apologies for Absence:		
	Prof Raphaela Kane	Pro Vice Chancellor, Faculty of Health, LJMU
	Jonathan Develing	Director of Strategic Partnerships

1. Apologies for Absence

Apologies noted above.

2. Declarations of Interest

No declarations of Interest noted at this meeting.

3. Minutes of the previous meeting on 12th December 2023

Minutes of the previous meeting on 12th December were agreed as an accurate record of the meeting.

Action

4. Action log

Action 1: Update on the implementation plan on the agenda for discussion. Action closed.

5. Research Strategy/Implementation Review

JC presented a research strategy update to colleagues and noted that the strategy was approved in 2023. The strategy includes three sections: people, process and money. People includes training and education, PIs and CIs, PPID, Research Lab and a joint academic post. Process includes governance structure, oversight and policies and procedures. Money includes commercial income, CRN income, grants and RCF.

JC provided an overview of the first-year objectives, year three objectives, year 5 objectives and highlighted the next steps.

Comments and questions were welcomed, and JW added that the 2022/23 year was really hard for Research and the department struggled financially. JW reassured the committee that the research department are now back on track and in a good position. It was also noted that there is a better structure within the nursing team and a new governance team. JW added that LHCH are due an MHRA inspection.

University Trust status was raised, and it was noted that the Walton Centre was recently awarded this and a query was raised on the case they put forward. It was added whether a conversation was warranted on the criteria with the university hospitals association. JC noted that the association are open to looking at the whole application, rather than just research capacity funding. JC agreed to pick this back up and take this forward.

JC

IJ added that one of the areas that was not met was Nursing and Allied Health Professional research and added that there is a group in Liverpool mentoring and focused on these groups. There is also 35 researchers at LJMU with a clinical background and would be confident and happy to provide support.

IJ raised the EDEPI Project. The EDEPI Programme was created to tackle persistent inequalities that create barriers to access and participation in doctoral education for racially minoritised groups. IJ noted that as part of this project, Trusts are being asked to come up with the research projects and LJMU funds the PhD fees. Discussion took place and KW queried why the Trust are not asking patients about what research is relevant and important for them. IJ agreed that this work would be collaborative and the PPI groups would be key to this.

LB suggested a survey for large scale feedback to allow patient voice to steer research. JC noted that this is something that the Trust could facilitate and something that KW has been asking for.

Chair highlighted the importance of publishing the successes of LHCH research and suggested that the website page requires work. JC provided assurance that the team are focused on improving this.

6. Report on LCCS

JC presented an update on the potential themes and informed colleagues that four themes had agreed. The four themes include, atrial fibrillation and stroke, hypertension, metabolic and vascular studies, heart failure/imaging and CVD prevention, rehabilitation, sports and exercise science.

KW noted that social media highlights that LCCS is mainly focused on AF and suggested that there is more oversight on the other themes. Chair agreed and added that this has been the aim of the oversight group, to broaden the themes.

7. Ongoing and Planned Research Project reports

JW provided an update on ongoing and planned research projects and informed colleagues that there was a site initiation visit for the first CRF study.

8. Partnership working and update from the partners

RS informed colleagues of a new starter within Pharmacology, that would be happy to meet with clinical colleagues.

RS also informed colleagues that University of Liverpool, unfortunately did not get the BHF award and are still awaiting the outcome of the accelerator status.

9. Research news and key successes

There was nothing raised at this meeting.

10. Report on Innovation agenda

Chair noted that the committee are still waiting to see an innovation strategy. JC confirmed that JD will be looking at reviewing this before leaving and LB added that this will be discussed at the Board Development Day.

12. Strategic R&I Business Cycle

Colleagues were asked to note the Strategic R&I Business cycle and this was approved by the committee.

13. Strategic R&I Committee Terms of Reference

Colleagues were asked to note the Strategic R&I Committee Terms of Reference.

Chair raised the membership of the committee and it was agreed that LB will review the membership and update colleagues.

LB

Date and time of next meeting:

Tuesday 14th May, 2.00pm – 3.30pm, MS Teams

